Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation

Keyphrases

• Antithrombotic Therapy 100%
• New-onset Atrial Fibrillation 100%
• Antiplatelet 100%
• Treatment Patterns 100%
• Atrial Fibrillation 66%
• Baseline Characteristics 66%
• Vitamin K Antagonists 66%
• Anticoagulants 66%
• CHA2DS2-VASc 66%
• Hypertension 33%
• Diabetes 33%
• Non-steroidal Anti-inflammatory Drugs (NSAIDs) 33%
• Vascular Disease 33%
• Anticoagulant Therapy 33%
• Stroke Risk 33%
• Newly Diagnosed 33%
• Newly Diagnosed Patients 33%
• Antiplatelet Monotherapy 33%
• Current Smokers 33%
• As(III) 33%
• Stroke Risk Factors 33%
• Elderly Patients 33%
• Renal Comorbidities 33%
• Cardiac Failure 33%
• Dementia 33%
• Vascular Comorbidity 33%
• Asian Ethnicity 33%
• Paroxysmal Atrial Fibrillation 33%
• Guideline-directed Medical Therapy 33%
• Working Diagnosis 33%
• Disease Age 33%
• Non-vitamin K Antagonists 33%

Medicine and Dentistry

• Antithrombotic 100%
• Atrial Fibrillation 100%
• Oral 100%
• Antiplatelet 80%
• Apoplexy 60%
• Vitamin K Antagonist 60%
• CHA2DS2-VASc Score 40%
• Antithrombotic Therapy 40%
• Diabetes 20%
• Nonsteroid Antiinflammatory Agent 20%
• Monotherapy 20%
• Anticoagulant Therapy 20%
• Congestive Heart Failure 20%
• Vascular Disease 20%
• Elderly Patient 20%
• Comorbidity 20%
• Hypertension 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticoagulant Agent 100%
• Atrial Fibrillation 100%
• Antiplatelet 100%
• Antivitamin K 75%
• Cerebrovascular Accident 75%
• Vitamin K Antagonist 75%
• Antithrombotic Therapy 50%
• Monotherapy 25%
• Non-Steroidal Anti-Inflammatory Drug 25%
• Congestive Heart Failure 25%
• Vascular Disease 25%
• Comorbidity 25%
• Hypertension 25%